Sorry about the confusion, yes skipping was the wrong phrase. Combining 2 and 3 or any way of fast tracking/decreasing the sample size would result it potential cost and time cuttings.
Yes, CUV has their SCENESSE product available in the EU and I believe Switzerland. Apparently US users are flying to Europe and pay for the treatment privately as FDA approval is still pending. I do not know how the process for the approval within the EU is working. Is there actually work being down by PAR to achieve that approval from the EU?
Sorry about the confusion, yes skipping was the wrong phrase....
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 21.0¢ | 19.5¢ | $80.51K | 398.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 112938 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 4396 | 1 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |